OSAKA, Japan--(BUSINESS WIRE)--Shionogi & Co., Ltd. (Head Office: Osaka, Japan; Chief Executive Officer: Isao Teshirogi, Ph.D.; hereafter “Shionogi”) delivered a late-breaking scientific oral ...
Single-tablet therapy for HIV Researchers evaluated adherence to nonoccupational post-exposure prophylaxis following potential HIV exposure. A single-tablet regimen consisting of DOR/3TC/TDF for ...
The MarketWatch News Department was not involved in the creation of this content. Late-Breaking at CROI 2025: SCORPIO-PEP Phase 3 Trial: Ensitrelvir is the First and Only COVID-19 Oral Antiviral to ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results